# Immunologic, Inflammatory, and Clinical contributors to HIV-Related Heart Failure with Preserved Ejection Fraction (HFpEF)

> **NIH NIH R01** · NORTHWESTERN UNIVERSITY · 2021 · $661,647

## Abstract

SUMMARY
The purpose of this application is to determine clinical, immunologic, and inflammatory factors that lead to
heart failure with preserved ejection fraction (HFpEF) for people with human immunodeficiency virus (HIV),
with the clinically relevant goal of improving HFpEF screening, prevention, and therapy for people with HIV
(PWH). HFpEF is a complex syndrome with high mortality: 50% of persons with HFpEF die within 5 years of
diagnosis. Rates of HFpEF and diastolic dysfunction – the key structural abnormality underlying HFpEF – are
significantly higher for PWH than people without HIV, with recent studies finding a 4-8-fold higher prevalence of
diastolic dysfunction for PWH than people without HIV. In general, inflammation and immune dysfunction are
important precipitants of HFpEF, and may be particularly important for HIV-associated HFpEF. However, data
are limited regarding HFpEF clinical risk factors and pathophysiology in PWH. One key reason for this
continued scientific gap is that no large, diverse, multi-center cohorts of PWH have adjudicated heart failure
events or linked these to biospecimens – a necessary step to accurately characterize and investigate specific
subtypes of heart failure. We propose to do this in a large, modern cohort of >35,000 PWH in clinical care
throughout the United States; this cohort has an extensive array of individually-linked bio-specimens, patient-
reported outcomes, and access to clinical imaging data that are unique among large HIV cohorts and
necessary to comprehensively characterize HFpEF in HIV. Our central hypothesis is that PWH with incomplete
immune recovery, as indicated by lower CD4 counts and CD4/CD8 ratios, are especially susceptible to HFpEF
in the presence of “second hits” ranging from hypertension to specific ART classes associated with off-target
comorbidities (such as weight gain). In the first aim, we will investigate clinical risk factors and interactions
thereof which are most strongly associated with incident HFpEF for PWH. In the second aim, we seek to more
deeply understand the biology of HIV-associated HFpEF and will therefore leverage a multi-marker proteomics
panel – for which we have extensive pilot data in non-HIV HFpEF patients – to define immunologic and
inflammatory contributors to HFpEF for PWH. In Aim 3, we will use a novel method to determine, at a single-
cell level, meaningful differences in immune cell gene expression that may lead to systemic biomarker
abnormalities and HFpEF for PWH; we will validate these findings in cardiac tissue in Aim 4. We have data to
support the premise and feasibility of each aim, and our PI is ideally suited to lead the proposed analyses; as a
cardiologist, he recently served as writing chair of the American Heart Association's scientific statement on HIV
and CVD, a landmark document that required extensive multidisciplinary coordination. Led by the PI, our team
has the requisite methods and content expertise to successfully perform the an...

## Key facts

- **NIH application ID:** 10161334
- **Project number:** 1R01HL156792-01
- **Recipient organization:** NORTHWESTERN UNIVERSITY
- **Principal Investigator:** Matthew Joel Feinstein
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $661,647
- **Award type:** 1
- **Project period:** 2021-02-25 → 2025-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10161334

## Citation

> US National Institutes of Health, RePORTER application 10161334, Immunologic, Inflammatory, and Clinical contributors to HIV-Related Heart Failure with Preserved Ejection Fraction (HFpEF) (1R01HL156792-01). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10161334. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*